E-Selectin Nasal Instillation to Prevent Secondary Stroke
Suspended
Phase 1 Results N/ASummary of Purpose
This study will determine the maximum safe dose of the experimental drug E-selectin that can be given to stroke patients. E-selectin causes white blood cells called lymphocytes to change so that they prevent clots from forming in the vessels that supply blood to the brain. The drug has been shown to be effective in animal models of stroke. This study will look at the safety of using this experimental drug in...
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 21 April 2018.
1 Oct 2003 | 12 Jul 2006 | 20 Nov 2025 | 20 Nov 2025 | 12 Mar 2018 | Unavailable |
Start Date | First Received | 1st Completion | Completion | Verification | Results |
---|
Trial Basics
Interventions
Conditions
Sponsors
Trial Design
- Allocation: Non-Randomized
- Masking: Open Label
- Purpose: Prevention
- Endpoint: Safety Study
- Intervention: Single Group Assignment
Contacts
- Patient Recruitment and Public Liaison Office
prpl@mail.cc.nih.gov (800) 411-1222
- TTY
1-866-411-1010
- John M Hallenbeck, M.D.
View Trial Locations
Recruitment
- Enrollment: 58
- Gender: All
- Minimum Age: 45 Years
- Accepts Healthy Volunteers: No
- 1 location, 1 country
Principal Investigator
- John M Hallenbeck, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)